For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, PTC Therapeutics Inc’s stock clocked out at $55.31, down -1.71% from its previous closing price of $56.27. In other words, the price has decreased by -$1.71 from its previous closing price. On the day, 0.61 million shares were traded. PTCT stock price reached its highest trading level at $56.2 during the session, while it also had its lowest trading level at $54.26.
Ratios:
To gain a deeper understanding of PTCT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.31 and its Current Ratio is at 2.35.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on March 11, 2025, Upgraded its rating to Neutral and sets its target price to $55 from $41 previously.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Perform rating and target price of $55.
Morgan Stanley Upgraded its Equal-Weight to Overweight on December 13, 2024, whereas the target price for the stock was revised from $45 to $67.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 17 ’25 when Pauwels Eric sold 6,762 shares for $56.80 per share. The transaction valued at 384,067 led to the insider holds 72,640 shares of the business.
Pauwels Eric sold 4,458 shares of PTCT for $246,037 on Mar 14 ’25. The CHIEF BUSINESS OFFICER now owns 79,402 shares after completing the transaction at $55.19 per share. On Mar 13 ’25, another insider, Okey Stephanie, who serves as the Director of the company, sold 5,000 shares for $54.00 each. As a result, the insider received 270,000 and left with 8,867 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 4437980672 and an Enterprise Value of 5679881728. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.41. Its current Enterprise Value per Revenue stands at 7.04 whereas that against EBITDA is -79.904.
Stock Price History:
The Beta on a monthly basis for PTCT is 0.54, which has changed by 0.9113451 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, PTCT has reached a high of $58.38, while it has fallen to a 52-week low of $24.00. The 50-Day Moving Average of the stock is 9.83%, while the 200-Day Moving Average is calculated to be 34.09%.
Shares Statistics:
It appears that PTCT traded 741.69K shares on average per day over the past three months and 813240 shares per day over the past ten days. A total of 77.70M shares are outstanding, with a floating share count of 76.82M. Insiders hold about 2.60% of the company’s shares, while institutions hold 97.64% stake in the company. Shares short for PTCT as of 1741910400 were 4302958 with a Short Ratio of 5.80, compared to 1739491200 on 3696224. Therefore, it implies a Short% of Shares Outstanding of 4302958 and a Short% of Float of 8.38.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of PTC Therapeutics Inc (PTCT) involves the perspectives of 2.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$1.24, with high estimates of -$0.87 and low estimates of -$1.6.
Analysts are recommending an EPS of between -$2.96 and -$4.28 for the fiscal current year, implying an average EPS of -$3.43. EPS for the following year is -$1.83, with 3.0 analysts recommending between -$0.1 and -$2.73.
Revenue Estimates
In the current quarter, 11 analysts expect revenue to total $437.16M. It ranges from a high estimate of $1.18B to a low estimate of $149.2M. As of the current estimate, PTC Therapeutics Inc’s year-ago sales were $210.12MFor the next quarter, 11 analysts are estimating revenue of $166.18M. There is a high estimate of $191M for the next quarter, whereas the lowest estimate is $136.3M.
A total of 14 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $1.75B, while the lowest revenue estimate was $655.6M, resulting in an average revenue estimate of $955.37M. In the same quarter a year ago, actual revenue was $806.78MBased on 14 analysts’ estimates, the company’s revenue will be $864.21M in the next fiscal year. The high estimate is $1.03B and the low estimate is $740M.
